Total Payments
$110,197
2024 Payments
$3,850
Companies
29
Transactions
248
Medicare Patients
757
Medicare Billing
$206,553
Payment Breakdown by Category
Other$54,725 (49.7%)
Consulting$32,530 (29.5%)
Travel$12,718 (11.5%)
Food & Beverage$7,820 (7.1%)
Research$2,154 (2.0%)
Education$250.57 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,725 | 16 | 49.7% |
| Consulting Fee | $32,530 | 13 | 29.5% |
| Travel and Lodging | $12,718 | 36 | 11.5% |
| Food and Beverage | $7,820 | 170 | 7.1% |
| Unspecified | $2,154 | 4 | 2.0% |
| Education | $250.57 | 9 | 0.2% |
Payments by Type
General
$108,043
244 transactions
Research
$2,154
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $44,480 | 44 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $33,306 | 24 | $0 (2017) |
| Amgen Inc. | $21,681 | 24 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $2,493 | 20 | $0 (2024) |
| PFIZER INC. | $1,600 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,592 | 6 | $0 (2022) |
| Astellas Pharma US Inc | $997.15 | 36 | $0 (2024) |
| Janssen Biotech, Inc. | $897.47 | 36 | $0 (2024) |
| KADMON PHARMACEUTICALS LLC | $390.00 | 1 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $365.87 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,850 | 55 | PFIZER INC. ($1,600) |
| 2023 | $1,074 | 33 | Astellas Pharma US Inc ($257.82) |
| 2022 | $1,812 | 10 | AstraZeneca Pharmaceuticals LP ($1,467) |
| 2021 | $1,758 | 9 | Novartis Pharmaceuticals Corporation ($1,298) |
| 2020 | $7,130 | 11 | Takeda Pharmaceuticals U.S.A., Inc. ($4,257) |
| 2019 | $27,225 | 31 | Takeda Pharmaceuticals U.S.A., Inc. ($17,319) |
| 2018 | $33,252 | 49 | Takeda Pharmaceuticals U.S.A., Inc. ($22,798) |
| 2017 | $34,097 | 50 | Millennium Pharmaceuticals, Inc. ($33,306) |
All Payment Transactions
248 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Janssen Scientific Affairs, LLC | TECVAYLI (Biological), TALVEY, CARVYKTI | Food and Beverage | In-kind items and services | $45.74 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $19.12 | General |
| 10/29/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $33.27 | General |
| 10/22/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $10.21 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $32.44 | General |
| Category: Rare Disease | ||||||
| 09/20/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Monoclonal Antibody | ||||||
| 09/06/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $2.22 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $28.99 | General |
| Category: Infectious Diseases | ||||||
| 08/29/2024 | Janssen Scientific Affairs, LLC | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $22.67 | General |
| 08/22/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $53.60 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Education | In-kind items and services | $30.29 | General |
| Category: Hematology | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Immunology | ||||||
| 08/19/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $27.44 | General |
| 08/15/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $28.90 | General |
| Category: ONCOLOGY | ||||||
| 08/07/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Immunology | ||||||
| 08/01/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $553.91 | Research |
| Study: CYTB323A12101 | ||||||
| 07/22/2024 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $15.59 | General |
| 07/09/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $39.55 | General |
| 06/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: IMMUNOLOGY | ||||||
| 06/20/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,600 | 3 |
| CYTB323A12101 | Novartis Pharmaceuticals Corporation | $553.91 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 184 | 569 | $110,230 | $49,420 |
| 2022 | 7 | 207 | 622 | $119,928 | $49,693 |
| 2021 | 6 | 237 | 880 | $171,947 | $75,754 |
| 2020 | 4 | 129 | 415 | $77,174 | $31,687 |
Total Patients
757
Total Services
2,486
Medicare Billing
$206,553
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 52 | 324 | $65,448 | $30,162 | 46.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 51 | 143 | $22,022 | $10,675 | 48.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 40 | $15,720 | $5,240 | 33.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 31 | 41 | $4,100 | $2,060 | 50.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 18 | 21 | $2,940 | $1,282 | 43.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 43 | 355 | $71,710 | $28,411 | 39.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 67 | 149 | $22,946 | $10,734 | 46.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 31 | 39 | $15,327 | $5,967 | 38.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 22 | 31 | $3,100 | $1,654 | 53.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 14 | 14 | $3,598 | $1,505 | 41.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 15 | 17 | $2,380 | $932.60 | 39.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 15 | 17 | $867.00 | $488.52 | 56.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 58 | 484 | $97,768 | $40,090 | 41.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 77 | 269 | $41,426 | $21,616 | 52.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 35 | 51 | $20,043 | $8,187 | 40.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $5,610 | $2,534 | 45.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 27 | 30 | $4,200 | $1,747 | 41.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 23 | 29 | $2,900 | $1,580 | 54.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 27 | 188 | $37,976 | $15,726 | 41.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 58 | 182 | $28,028 | $11,449 | 40.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 29 | 29 | $9,570 | $3,923 | 41.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 15 | 16 | $1,600 | $588.84 | 36.8% |
About Dr. Aravind Ramakrishnan, M.D
Dr. Aravind Ramakrishnan, M.D is a Medical Oncology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174686364.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aravind Ramakrishnan, M.D has received a total of $110,197 in payments from pharmaceutical and medical device companies, with $3,850 received in 2024. These payments were reported across 248 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($54,725).
As a Medicare-enrolled provider, Ramakrishnan has provided services to 757 Medicare beneficiaries, totaling 2,486 services with total Medicare billing of $206,553. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Austin, TX
- Active Since 12/18/2006
- Last Updated 12/26/2014
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1174686364
Products in Payments
- NINLARO (Drug) $74,840
- Blincyto (Biological) $16,055
- Kyprolis (Biological) $3,996
- KYMRIAH (Biological) $1,650
- ELREXFIO (Drug) $1,600
- DARZALEX (Biological) $618.83
- Cresemba (Drug) $452.92
- CRESEMBA (Drug) $256.30
- Yescarta (Drug) $232.44
- TECVAYLI (Biological) $231.16
- DARZALEX (Drug) $210.75
- IMBRUVICA (Drug) $202.60
- CARVYKTI (Biological) $168.59
- REZUROCK (Drug) $168.38
- MOZOBIL (Drug) $157.05
- Vanflyta (Drug) $156.07
- SOLIRIS (Drug) $155.00
- ADCETRIS (Biological) $149.07
- SARCLISA (Biological) $148.36
- VYXEOS (Drug) $140.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Austin
Dr. Jason Melear, M.d, M.D
Medical Oncology — Payments: $534,206
Medical Oncology $534,206
Sue Eckhardt, Md, MD
Medical Oncology — Payments: $419,765
Medical Oncology $419,765
Miguel Albino, Md, MD
Medical Oncology — Payments: $308,516
Medical Oncology $308,516
Michael Lattanzi
Medical Oncology — Payments: $155,982
Medical Oncology $155,982
Dr. Laurence Tokaz, M.d, M.D
Medical Oncology — Payments: $46,331
Medical Oncology $46,331
Dr. John Sandbach, Md, MD
Medical Oncology — Payments: $7,649
Medical Oncology $7,649